Author Archives: Marisa Wexler MS

Long-term Vyndaqel Improves Survival in FAP, Study Suggests

Long-term treatment with Vyndaqel (tafamidis) may reduce the risk of death in people with familial amyloid polyneuropathy (FAP), a study shows. The study, “Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years,” were…

Onpattro Approved in Brazil to Treat Adults With FAP

Onpattro (patisiran) has been approved in Brazil to treat hereditary transthyretin amyloidosis in adults with stage 1 or stage 2 polyneuropathy, the therapy’s developer, Alnylam Pharmaceuticals, has announced. Hereditary ATTR amyloidosis, also known as familial amyloid polyneuropathy (FAP), is a genetic…

Longer Wait for Liver Transplant Can Worsen FAP Afterward, Study Finds

Liver transplants can significantly prolong survival in familial amyloid polyneuropathy (FAP) patients, and the longer they must wait for the transplant may mean the disease will worsen after the procedure. Those findings come from the study “Liver Transplantation for Familial Amyloid Polyneuropathy (Val30Met): Long-Term Follow-up Prospective Study…